Document is current

Any future updates will be listed below

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark

Crossref DOI link: https://doi.org/10.1007/s13300-022-01323-y

Published Online: 2022-10-31

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark